Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2022-03-23 Major Shareholding Noti…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BOTHE_PR_2022-03-23_Transparency Notification_Nyenburgh_FR_Final.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE" (Press Release - Regulated Information) and explicitly announces the receipt of a "Notification de transparence" (Transparency Notification) regarding a change in significant shareholding (Nyenburgh Holding NV crossing the 5% threshold downwards). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Although it is a press release, the core content is the regulatory notification itself, making MRQ a more specific fit than the general Regulatory Filings (RNS).
2022-03-23 French
Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook
Earnings Release Classification · 98% confidence The document is titled "Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook" and is dated January 19, 2022. It provides a summary of operational and financial highlights for Q4 2021 and outlines the outlook for 2022. This content structure—a summary of recent performance and future guidance, typically released shortly after the end of a period but before the full statutory report—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). The financial calendar at the end explicitly mentions the 'Full Year Results & Annual Report 2021' will be released on April 27, confirming this document is the preliminary announcement. Q4 2021
2022-01-19 English
Bone Therapeutics fait le point sur ses activités au quatrième trimestre 2021 et sur ses perspectives de développement en 2022
Earnings Release Classification · 95% confidence The document is titled "Bone Therapeutics fait le point sur ses activités au quatrième trimestre 2021 et sur ses perspectives de développement en 2022" (Bone Therapeutics provides an update on its Q4 2021 activities and 2022 development outlook). It details operational highlights, corporate developments, financial elements (cash position, cost management), and a financial calendar for 2022, including dates for the 'Résultats annuels et rapport annuel 2021' (Annual results and annual report 2021) and the 'Assemblée Générale Annuelle 2022' (Annual General Meeting 2022). The content strongly suggests a periodic business update covering the end of a fiscal year (Q4 2021) and forward-looking statements, which is characteristic of an Earnings Release (ER) or a Management Discussion & Analysis (MDA). Since it provides key financial figures (cash position, net cash burn) and operational updates, but is explicitly framed as a 'COMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE' (Press Release - Regulated Information) providing an update rather than the full, detailed Annual Report (10-K), it fits best as an Earnings Release (ER). It is not the full 10-K because it explicitly schedules the 'rapport annuel 2021' for April 27th. It is more detailed than a simple NAV or DIV announcement. It is a comprehensive update on performance and outlook, aligning with the definition of an Earnings Release (ER) which provides initial announcements of periodical financial results (key highlights). Q4 2021
2022-01-19 French
Notiication de transparence au 07.12.2021.pdf
Major Shareholding Notification Classification · 98% confidence The document is a formal notification, structured with numbered sections typical of regulatory filings. Key indicators are 'Statut de la notification' (Notification Status), 'Emetteur' (Issuer), 'Motif de la notification' (Reason for notification), and specific details about thresholds crossed ('Franchissement de seuil passif'). Section 8 explicitly mentions a threshold crossed ('Seuil franchi (en %)') and Section 10 details voting rights ('Droits de vote'). This structure strongly suggests a mandatory disclosure regarding changes in significant shareholdings or control, which aligns with the definition of Major Shareholding Notification (MRQ). The content is not an Annual Report (10-K), an Earnings Release (ER), or a proxy statement (DEF 14A/PSI).
2021-12-23 French
BOTHE_PR_2021-12-23_Transparency Notification_SRIW_EN_Final.pdf
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled as a "Transparency notification received from S.R.I.W. SA and Sofipôle SA" and is dated December 23, 2021. It details a passive crossing of a major shareholding threshold (5%) by S.R.I.W. SA and Sofipôle SA, providing specific figures on voting rights before and after the transaction, as required by Article 14 of the Law of 2 May 2007 on disclosure of major holdings. This content directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Although it is presented as a press release, the core regulatory information being disclosed is the change in major shareholding.
2021-12-23 English
BOTHE_PR_2021-12-23_Transparency Notification_SRIW_FR_Final.pdf
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE" (Press Release - Regulated Information) and announces the receipt of a "Notification de transparence" (Transparency Notification) regarding a change in significant shareholding (crossing the 5% threshold). This type of filing, which reports changes in major share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is presented as a press release, the core content is the regulatory disclosure of ownership change, not a general regulatory announcement (RNS) or a report publication announcement (RPA).
2021-12-23 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.